Drug Monograph Digest is a curated reference of drug monographs compiled from primary, publicly available sources such as FDA approval letters and labels, NDA reviews, the Orange Book, and other regulatory materials. Each entry follows a consistent format designed to surface the information that drives strategic, regulatory, and business decisions. Coverage currently centers on drugs approved under the FDA's 505(b)(2) pathway and will expand to additional pathways and drug categories over time.
Comprehensive 505(b)(2) Monographs — and Why They Matter
The FDA's 505(b)(2) pathway offers a way to win NDA approval using existing clinical or toxicology data, whether from previously approved drugs or published literature, rather than starting from scratch. It's the go-to route for new formulations, strengths, combinations, and repurposed drugs. More than 50 NDAs are approved this way each year, and many open the door to valuable life cycle management opportunities. Since these approvals build on data that already exists, the clinical studies, if any, tend to be smaller and more focused than those behind a brand-new NDA, but the commercial upside can still be substantial. There's no single, reliable source that pulls this information together. So learning from what others have already done means rebuilding each regulatory history piece by piece across Drugs@FDA, the Orange Book, and approval letters scattered through separate federal sources. Drug Monograph Digest closes that gap.